300110 华仁药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.6937.1997.3755.6334.270
总资产报酬率 ROA (%)1.4433.6423.3462.8803.089
投入资产回报率 ROIC (%)1.5994.0263.8183.4123.192

边际利润分析
销售毛利率 (%)37.75542.72343.27250.58242.857
营业利润率 (%)11.45213.80912.2569.6938.662
息税前利润/营业总收入 (%)15.25517.95916.75413.9938.960
净利润/营业总收入 (%)9.94411.82111.1958.5887.359

收益指标分析
经营活动净收益/利润总额(%)100.525100.402108.010152.499142.726
价值变动净收益/利润总额(%)0.4090.366-0.673-0.577-0.639
营业外收支净额/利润总额(%)-1.3991.9833.579-0.693-2.155

偿债能力分析
流动比率 (X)1.7361.8411.3451.2001.513
速动比率 (X)1.5251.6201.2141.0931.268
资产负债率 (%)43.49246.45549.64556.68931.797
带息债务/全部投入资本 (%)37.74541.40041.87642.782--
股东权益/带息债务 (%)162.249139.113129.542115.394409.500
股东权益/负债合计 (%)126.648112.26698.74274.148207.975
利息保障倍数 (X)3.8514.6394.1443.20518.620

营运能力分析
应收账款周转天数 (天)147.671142.065160.014162.4820.000
存货周转天数 (天)122.517115.520106.255124.7140.000